Welcome to our dedicated page for Marpai news (Ticker: MRAI), a resource for investors and traders seeking the latest updates and insights on Marpai stock.
Marpai, Inc. (MRAI) is a technology platform company whose subsidiaries provide Third-Party Administration (TPA), Pharmacy Benefit Management (PBM) and value-oriented health plan services to employers that directly pay for employee health benefits. This news page aggregates company-issued updates and related coverage so readers can follow how Marpai describes its progress in the self-funded employer health plan market.
Recent Marpai news has focused on its turnaround strategy, cost discipline and operational efficiency, as well as developments in its TPA and PBM offerings. The company has reported reductions in operating expenses and changes in operating loss and net loss over multiple quarters, and it links these trends to efforts to streamline operations and adjust its business model. News releases also highlight private placements and other capital transactions disclosed in Form 8-K filings, which Marpai states are intended to support working capital and general corporate purposes.
Marpai’s updates describe initiatives such as the Marpai Saves program and the relaunch of MarpaiRx, its PBM solution, which the company positions as part of its approach to serving self-funded employer health plans. Other announcements discuss network access agreements, including access to the Aetna Signature Administrator PPO network, and the addition of tools like the Aetna Faircost Optimizer for managing out-of-network claims costs.
Investors and observers can use this news feed to review Marpai’s own descriptions of its financial results, strategic initiatives, technology platform developments and capital raising activities. For a fuller picture, readers may compare these news items with the company’s SEC filings and other official disclosures.
Summary not available.
Marpai, Inc. (Nasdaq: MRAI) has launched the myMarpai Medical Shopping Tool, designed to enhance price transparency for members of self-funded employer health plans. This tool provides upfront medical service pricing, promoting informed healthcare decisions and compliance with the Transparency in Coverage Rule and No Surprises Act. By integrating behavioral economics with technology, it facilitates comparisons on price, quality, and convenience, aiming to lower costs for employers.
Marpai, Inc. (NASDAQ: MRAI) has appointed Gonen Antebi as its new Chief Operating Officer, bringing significant experience from his tenure as CEO at Nuvem Health. Mr. Antebi has previously led operations at ArroHealth and MedSave USA, enhancing healthcare delivery and profitability. He replaces Ronnie Brown, who will continue to serve as an advisor. Antebi's leadership is expected to drive Marpai's growth in the TPA sector, particularly following the recent acquisition of Maestro Health. Marpai aims to leverage AI technology to optimize self-funded employer health plans and enhance cost efficiency.
Summary not available.
Marpai (Nasdaq: MRAI) announced the addition of Virta Health as a Premium Health Partner to enhance diabetes management for its health plan members. This partnership aims to provide effective solutions for reversing type 2 diabetes, addressing the growing issue that affects nearly 133 million Americans. Virta's approach focuses on sustainable health improvements without the typical risks associated with medications. Marpai's Proactive Targeted Health Interventions will make Virta's services available to all members upon renewal or new enrollment beginning January 1, 2023.
Marpai, Inc. (Nasdaq: MRAI) reported Q3 2022 financial results, with net revenue of approximately $4.9 million, down 11.1% from Q2 2022. This decline was attributed to a reduction in employees covered under their plans, which dropped to 16,357 by September 30, 2022. Operating expenses decreased to around $10.8 million, yet the net loss was approximately $5.8 million. Following the acquisition of Maestro Health, Marpai aims to integrate operations and expand its customer base significantly. Financial guidance for Q4 2022 remains undisclosed due to the acquisition.
Marpai, Inc. (Nasdaq: MRAI) will hold a conference call on November 10, 2022, at 8:30 a.m. ET to discuss its Q3 2022 financial results. The results will be released after market close on November 9, 2022. Marpai operates in the $22 billion Third Party Administrator sector, focusing on self-funded health plans. With AI-driven services, the company aims to enhance health outcomes and value-based care while managing substantial annual claims exceeding $1 trillion.
Marpai, Inc. (Nasdaq: MRAI) has launched MarpaiRx, an innovative pharmacy benefit management (PBM) solution aimed at lowering drug costs for self-insured health plans. Collaborating with MedOne Pharmacy Benefit Solutions, MarpaiRx focuses on enhancing member experiences and reducing costs through a patient-centric approach. It offers a formulary based on drug outcome performance and ensures transparency by passing all discounts directly to clients. Leveraging AI technology, MarpaiRx aims to simplify access to affordable medications while addressing the growing expenses associated with pharmacy benefits.
Marpai, Inc. (MRAI) reported Q2 2022 results, with net revenue of approximately $5.6 million, down 10.6% from Q1's $6.2 million. The decline was attributed to a drop in employees covered under its health plans, decreasing to 21,074 from 25,195 a year prior. Operating expenses rose to $12.2 million, while net loss widened to $6.7 million compared to $5.5 million in the previous quarter. The company is focused on its January 1, 2023 sales period and the upcoming acquisition of Maestro Health, which may impact future results.
Marpai, Inc. (Nasdaq: MRAI) announced its definitive agreement to acquire Maestro Health, a leading Third-Party Administrator (TPA) based in Chicago, for $22.1 million. This acquisition, expected to close within 60 days, will combine resources, doubling Marpai's revenues and expanding its customer base to over 40,000 employee lives with projected combined revenues of $40 million in 2022. The merger includes over $20 million in cash expected at closing to finance integration and aims for positive EBITDA within 18 months.